Improves Tissue Yield on Slides

• It enhances tissue yield on slides by minimizing linear variability, leading to greater histologic tissue surface area and biopsy core length. In some labs, pathologists using the BxChip have even reported higher cancer detection rates.

Some labs have reported:

• 5% average increase in histologic tissue surface area on the glass slide
• 8% average increase in biopsy core length
• Up to a 9.3% increase in cancer detection rates!

Reduces Waste

• It reduces cassette and block volume in the lab, saving on materials, costs, tech time, and storage space.

Saves Time

• 78% reduction in grossing time
• 83% reduction in embedding time
• 76% decrease in total lab time per prostate case

Enhances Digital Pathology Capabilities

• It improves the quality of scanned slides by providing a blue material that serves as an anchor, allowing scanners to focus on the relevant areas.
• It ensures proper orientation of biopsy cores and accurate site designation.
• It offers a landmark for AI, enabling simultaneous viewing of multiple slides and levels from the same core on a grid.

Is it FDA-registered?

Yes! The BxChip is registered with the FDA. It also has CE marking, which certifies that a product has met EU health, safety, and environmental requirements, which ensure consumer safety.

“A couple years ago Dr. Kirk Wojno did a study where the prostate cancer detection rate increased from 49.5% to 58.8% when using the Lumea BxChip. If it’s your father’s prostate or your husband’s prostate biopsy you would want to know that extra 9.3%.”

Ann Mazurco, Histotechnologist